Across 32 United States jurisdictions, among males aged 18 to 49 years eligible for JYNNEOS vaccination, mpox incidence was 14 times as high among unvaccinated males compared with those who had received a first vaccine dose ≥ 14 days earlier (see CDC: Rates of Mpox Cases by Vaccination Status).